RS65359B1 - Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja - Google Patents
Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanjaInfo
- Publication number
- RS65359B1 RS65359B1 RS20240380A RSP20240380A RS65359B1 RS 65359 B1 RS65359 B1 RS 65359B1 RS 20240380 A RS20240380 A RS 20240380A RS P20240380 A RSP20240380 A RS P20240380A RS 65359 B1 RS65359 B1 RS 65359B1
- Authority
- RS
- Serbia
- Prior art keywords
- pharmaceutical composition
- treatment
- htbz
- use according
- hours
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461989240P | 2014-05-06 | 2014-05-06 | |
| EP21178882.3A EP3936130B1 (en) | 2014-05-06 | 2015-05-06 | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65359B1 true RS65359B1 (sr) | 2024-04-30 |
Family
ID=53264772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240380A RS65359B1 (sr) | 2014-05-06 | 2015-05-06 | Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja |
| RS20220008A RS62782B1 (sr) | 2014-05-06 | 2015-05-06 | Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20220008A RS62782B1 (sr) | 2014-05-06 | 2015-05-06 | Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20170071932A1 (enExample) |
| EP (3) | EP4389227A3 (enExample) |
| JP (4) | JP6635945B2 (enExample) |
| KR (5) | KR20220140647A (enExample) |
| CN (3) | CN112741835A (enExample) |
| AU (1) | AU2015256012B2 (enExample) |
| CA (1) | CA2947736C (enExample) |
| CY (1) | CY1125058T1 (enExample) |
| DK (2) | DK3139925T3 (enExample) |
| ES (2) | ES2904526T3 (enExample) |
| FI (1) | FI3936130T3 (enExample) |
| HR (2) | HRP20220025T1 (enExample) |
| HU (2) | HUE066361T2 (enExample) |
| IL (1) | IL248745B (enExample) |
| LT (2) | LT3139925T (enExample) |
| MX (1) | MX387625B (enExample) |
| NZ (1) | NZ725826A (enExample) |
| PL (2) | PL3139925T3 (enExample) |
| PT (2) | PT3139925T (enExample) |
| RS (2) | RS65359B1 (enExample) |
| RU (1) | RU2753740C2 (enExample) |
| SI (2) | SI3936130T1 (enExample) |
| SM (2) | SMT202400199T1 (enExample) |
| WO (1) | WO2015171802A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3875459T (lt) * | 2015-10-30 | 2024-02-26 | Neurocrine Biosciences, Inc. | Valbenazino dihidrochlorido druskos ir jų polimorfai |
| CA3009169A1 (en) * | 2015-12-23 | 2017-06-29 | Neurocrine Biosciences, Inc. | Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate) |
| EP3473623B1 (en) | 2016-06-29 | 2020-07-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal forms of nbi-98854, preparation method therefor and use thereof |
| JP2020500875A (ja) * | 2016-12-02 | 2020-01-16 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用 |
| US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
| JP7090151B2 (ja) | 2017-01-27 | 2022-06-23 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| US10954235B2 (en) | 2017-02-27 | 2021-03-23 | Sandoz Ag | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) * | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| JP2020512986A (ja) * | 2017-04-01 | 2020-04-30 | アデプティオ ファーマシューティカルズ リミテッド | 運動障害の治療に使用するための（＋）−α−ジヒドロテトラベナジン |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705305D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| US20190111035A1 (en) * | 2017-04-01 | 2019-04-18 | Adeptio Pharmaceuticals Limited | Pharmaceutical compositions |
| CN110691596A (zh) * | 2017-04-01 | 2020-01-14 | 阿德普蒂奥制药有限公司 | 药物组合物 |
| GB201705303D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| WO2018200605A1 (en) * | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| MA50175B1 (fr) | 2017-09-21 | 2025-05-30 | Neurocrine Biosciences, Inc. | Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| AU2017435893B2 (en) | 2017-10-10 | 2023-06-29 | Neurocrine Biosciences, Inc | Methods for the administration of certain VMAT2 inhibitors |
| WO2019094491A1 (en) * | 2017-11-08 | 2019-05-16 | Yuhua Li | Esters of dihydrotetrabenazine |
| CA3086611C (en) | 2017-12-26 | 2023-07-25 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof |
| CA3097189A1 (en) * | 2018-04-25 | 2019-10-31 | Shinkei Therapeutics Llc | Tetrabenazine transdermal delivery device |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| WO2019241555A1 (en) | 2018-06-14 | 2019-12-19 | Neurocrine Biosciences, Inc. | Vmat2 inhibitor compounds, compositions, and methods relating thereto |
| SG11202100303QA (en) | 2018-08-15 | 2021-02-25 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
| WO2020070236A1 (en) | 2018-10-04 | 2020-04-09 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| JOP20210274A1 (ar) * | 2019-05-09 | 2023-01-30 | Neurocrine Biosciences Inc | طرق لإعطاء مثبط vmat2 معين |
| US10940141B1 (en) * | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007317242B2 (en) | 2006-11-08 | 2013-08-01 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
| JP2010509336A (ja) * | 2006-11-09 | 2010-03-25 | ニューヨーク ユニバーシティ | サンドイッチ材料の製造方法、ガラス／セラミック／ガラス複合構造物、ガラス／セラミック／ガラス、医科あるいは歯科補綴、およびガラス／ジルコニア／ガラスサンドイッチ材料 |
| US20110053866A1 (en) * | 2008-08-12 | 2011-03-03 | Biovail Laboratories International (Barbados) S.R.L. | Pharmaceutical compositions |
| GB2462611A (en) | 2008-08-12 | 2010-02-17 | Cambridge Lab | Pharmaceutical composition comprising tetrabenazine |
| EP3345905B1 (en) | 2008-09-18 | 2021-09-01 | Auspex Pharmaceuticals, Inc. | Deuterated benzoquinolizine derivatives as inhibitors of vesicular monoamine transporter 2 |
| CA2771539A1 (en) * | 2009-08-12 | 2011-02-17 | Valeant International (Barbados) Srl | Pharmaceutical compositions with tetrabenzine |
| WO2011153157A2 (en) * | 2010-06-01 | 2011-12-08 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| JP6362601B2 (ja) * | 2012-09-18 | 2018-07-25 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態 |
| CN106061506A (zh) * | 2014-02-07 | 2016-10-26 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
-
2015
- 2015-05-06 KR KR1020227034399A patent/KR20220140647A/ko not_active Ceased
- 2015-05-06 CN CN202011483135.XA patent/CN112741835A/zh active Pending
- 2015-05-06 DK DK15724438.5T patent/DK3139925T3/da active
- 2015-05-06 HU HUE21178882A patent/HUE066361T2/hu unknown
- 2015-05-06 SM SM20240199T patent/SMT202400199T1/it unknown
- 2015-05-06 SM SM20220193T patent/SMT202200193T1/it unknown
- 2015-05-06 ES ES15724438T patent/ES2904526T3/es active Active
- 2015-05-06 CA CA2947736A patent/CA2947736C/en active Active
- 2015-05-06 RS RS20240380A patent/RS65359B1/sr unknown
- 2015-05-06 US US15/309,108 patent/US20170071932A1/en not_active Abandoned
- 2015-05-06 FI FIEP21178882.3T patent/FI3936130T3/fi active
- 2015-05-06 CN CN201580023821.XA patent/CN106456629A/zh active Pending
- 2015-05-06 KR KR1020207032879A patent/KR20200133003A/ko not_active Ceased
- 2015-05-06 IL IL248745A patent/IL248745B/en unknown
- 2015-05-06 PL PL15724438T patent/PL3139925T3/pl unknown
- 2015-05-06 KR KR1020247001490A patent/KR20240011255A/ko not_active Ceased
- 2015-05-06 LT LTEPPCT/US2015/029519T patent/LT3139925T/lt unknown
- 2015-05-06 DK DK21178882.3T patent/DK3936130T3/da active
- 2015-05-06 PT PT157244385T patent/PT3139925T/pt unknown
- 2015-05-06 WO PCT/US2015/029519 patent/WO2015171802A1/en not_active Ceased
- 2015-05-06 RS RS20220008A patent/RS62782B1/sr unknown
- 2015-05-06 HU HUE15724438A patent/HUE057839T2/hu unknown
- 2015-05-06 SI SI201532006T patent/SI3936130T1/sl unknown
- 2015-05-06 RU RU2016147523A patent/RU2753740C2/ru active
- 2015-05-06 NZ NZ725826A patent/NZ725826A/en unknown
- 2015-05-06 EP EP24157482.1A patent/EP4389227A3/en not_active Withdrawn
- 2015-05-06 KR KR1020257005033A patent/KR20250029267A/ko active Pending
- 2015-05-06 KR KR1020167033765A patent/KR20160147044A/ko not_active Ceased
- 2015-05-06 MX MX2016014429A patent/MX387625B/es unknown
- 2015-05-06 CN CN202011483141.5A patent/CN112741836A/zh active Pending
- 2015-05-06 PL PL21178882.3T patent/PL3936130T3/pl unknown
- 2015-05-06 EP EP21178882.3A patent/EP3936130B1/en active Active
- 2015-05-06 ES ES21178882T patent/ES2976207T3/es active Active
- 2015-05-06 SI SI201531799T patent/SI3139925T1/sl unknown
- 2015-05-06 EP EP15724438.5A patent/EP3139925B1/en active Active
- 2015-05-06 AU AU2015256012A patent/AU2015256012B2/en active Active
- 2015-05-06 HR HRP20220025TT patent/HRP20220025T1/hr unknown
- 2015-05-06 JP JP2016566238A patent/JP6635945B2/ja active Active
- 2015-05-06 PT PT211788823T patent/PT3936130T/pt unknown
- 2015-05-06 LT LTEP21178882.3T patent/LT3936130T/lt unknown
- 2015-05-06 HR HRP20240459TT patent/HRP20240459T1/hr unknown
-
2019
- 2019-10-02 JP JP2019181949A patent/JP2019218407A/ja not_active Withdrawn
- 2019-12-03 US US16/701,339 patent/US20200101063A1/en not_active Abandoned
-
2020
- 2020-09-15 US US17/021,362 patent/US20210196702A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021153918A patent/JP2021191799A/ja not_active Withdrawn
-
2022
- 2022-02-07 CY CY20221100104T patent/CY1125058T1/el unknown
-
2024
- 2024-07-29 JP JP2024122223A patent/JP2024153782A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS65359B1 (sr) | Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja | |
| HK40111840A (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| HK40067005B (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| HK1235303A1 (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| HK1235303B (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| HK40067005A (en) | Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders | |
| EP4082549A1 (en) | Drug for preventing dialysis shift or renal death | |
| US20250281499A1 (en) | Fused amino pyrimidine compounds for treatment of neuropathic and neuro-inflammatory pain | |
| US20250281500A1 (en) | Fused amino pyrimidine compounds and pridopidine for treatment of huntington’s disease | |
| US20250281498A1 (en) | Fused amino pyrimidine compounds for treatment of synucleinopathies and tdp-43 proteinopathies | |
| US9233103B2 (en) | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy | |
| Chaplin et al. | Drug points: Second‐generation antipsychotics | |
| Schmidt et al. | P. 3. c. 046 Efficacy and safety of JNJ 37822681, a fast dissociating D2 receptor antagonist, in the treatment of schizophrenia | |
| KR101432905B1 (ko) | 다폭세틴을 유효성분으로 포함하는 유전적 통증 치료용 약학 조성물 | |
| US20080070952A1 (en) | Inhibition or Treatment of Dyskinesia | |
| Vinall | Update on Safety Issues in the Treatment of Rheumatic Diseases. | |
| Willis et al. | P. 3. c. 044 Antipsychotic polypharmacy in a community psychiatric clinic | |
| JP2021522177A (ja) | イオン輸送体の活性を増強するための組成物および方法ならびにその使用 | |
| EP2255807A1 (en) | Method of treating sleep disorders using the combination of eplivanserin and zolpidem |